Product: Synuclein alpha Antibody
Catalog: AF0402
Description: Rabbit polyclonal antibody to Synuclein alpha
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Rabbit, Dog
Mol.Wt.: 18kDa; 14kD(Calculated).
Uniprot: P37840
RRID: AB_2833546

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

WB 1:500-1:3000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Pig(100%), Bovine(100%), Horse(100%), Rabbit(100%), Dog(100%)
Synuclein alpha Antibody detects endogenous levels of total Synuclein alpha.
Cite Format: Affinity Biosciences Cat# AF0402, RRID:AB_2833546.
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Store at -20 °C. Stable for 12 months from date of receipt.


Alpha synuclein; Alpha-synuclein; Alpha-synuclein, isoform NACP140; alphaSYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid; Non A4 component of amyloid precursor; Non-A beta component of AD amyloid; Non-A-beta component of alzheimers disease amyloid , precursor of; Non-A4 component of amyloid precursor; Non-A4 component of amyloid, precursor of; OTTHUMP00000218549; OTTHUMP00000218551; OTTHUMP00000218552; OTTHUMP00000218553; OTTHUMP00000218554; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease (autosomal dominant, Lewy body) 4; Parkinson disease familial 1; SNCA; Snca synuclein, alpha (non A4 component of amyloid precursor); SYN; Synuclein alpha; Synuclein alpha 140; Synuclein, alpha (non A4 component of amyloid precursor); SYUA_HUMAN;



Highly expressed in presynaptic terminals in the central nervous system. Expressed principally in brain.

SNCA a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson's disease. A major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced isoforms transcripts have been identified.



Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P37840 As Substrate

Site PTM Type Enzyme
M1 Acetylation
K6 Sumoylation
K10 Sumoylation
K12 Sumoylation
K12 Ubiquitination
K21 Acetylation
K21 Sumoylation
K21 Ubiquitination
K23 Sumoylation
K23 Ubiquitination
K34 Sumoylation
Y39 Phosphorylation
S42 Phosphorylation
K45 Sumoylation
T54 O-Glycosylation
K58 Acetylation
K60 Sumoylation
K80 Sumoylation
S87 O-Glycosylation
S87 Phosphorylation P48729 (CSNK1A1) , P68400 (CSNK2A1) , Q13627 (DYRK1A)
K96 Acetylation
K96 Sumoylation
K102 Sumoylation
Y125 Phosphorylation P06241 (FYN) , Q14289 (PTK2B) , P12931 (SRC) , P43405 (SYK)
S129 Phosphorylation P68400 (CSNK2A1) , P49841 (GSK3B) , P53350 (PLK1) , Q5S007 (LRRK2) , P25098 (GRK2) , P34947 (GRK5) , P48729 (CSNK1A1) , Q9UQM7 (CAMK2A) , P43250 (GRK6) , Q9H4B4 (PLK3) , Q9NYY3 (PLK2)
Y133 Phosphorylation P43405 (SYK)
Y136 Phosphorylation P43405 (SYK)

Research Backgrounds


Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. Mechanistically, acts by increasing local Ca(2+) release from microdomains which is essential for the enhancement of ATP-induced exocytosis. Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5. This chaperone activity is important to sustain normal SNARE-complex assembly during aging. Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity.


Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.

Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.

Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity).

Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure.

Subcellular Location:

Cytoplasm. Membrane. Nucleus. Cell junction>Synapse. Secreted.
Note: Membrane-bound in dopaminergic neurons.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Highly expressed in presynaptic terminals in the central nervous system. Expressed principally in brain.

Subunit Structure:

Soluble monomer. Homotetramer. A dynamic intracellular population of tetramers and monomers coexists normally and the tetramer plays an essential role in maintaining homeostasis. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones. Interacts (via N-terminus) with synphilin-1/SNCAIP; this interaction promotes formation of SNCA inclusions in the cytoplasm. Interacts with CALM1. Interacts with STXBP1; this interaction controls SNCA self-replicating aggregation. Interacts with SNARE components VAMP2 and SNAP25; these interactions allows SNARE complex assembly and integrity. Interacts with RPH3A and RAB3A. Interacts with SERF1A; this interaction promotes the aggregation of SNCA.


The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.

Belongs to the synuclein family.

Research Fields

· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.

· Human Diseases > Neurodegenerative diseases > Parkinson's disease.


1). Integrative multilevel exploration of the mechanism by which Er-Zhi-Wan alleviates the Parkinson's disease (PD)-like phenotype in the MPTP-induced PD mouse model. Biomedicine & Pharmacotherapy (PubMed: 37348406) [IF=7.5]

Application: WB    Species: Mouse    Sample:

Fig. 3. EZW reduces the dopaminergic neuron damage in MPTP-PD mice. (A) The expression of TH, α-syn, and DAT in the striatum of each group was measured by Western blot analysis (n = 3 per group). (B) Relative densities of TH, α-syn, DAT, and β-actin were measured in different groups using densitometric analysis of Western blots. TH, α-syn, and DAT proteins were normalized to β-actin, and were expressed as the fold difference relative to the control group (Data represent the mean ± SD, n = 3. * P 

2). Chitosan oligosaccharides exert neuroprotective effects via modulating the PI3K/Akt/Bcl-2 pathway in a Parkinsonian model. Food & Function (PubMed: 35545086) [IF=6.1]

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.